PainReform Ltd. (NASDAQ:PRFX) Sees Large Drop in Short Interest

PainReform Ltd. (NASDAQ:PRFX) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 27,647 shares, a drop of 59.7% from the September 15th total of 68,535 shares. Approximately 4.9% of the shares of the company are sold short. Based on an average daily trading volume, of 639,272 shares, the days-to-cover ratio is presently 0.0 days.

PainReform Price Performance

PainReform stock traded up $0.00 during mid-day trading on Wednesday, reaching $0.82. 50,335 shares of the company were exchanged, compared to its average volume of 1,211,524. The firm has a market cap of $712,356.00, a PE ratio of -0.00 and a beta of 1.08. The company has a fifty day simple moving average of $0.97 and a 200-day simple moving average of $1.46. PainReform has a 12 month low of $0.81 and a 12 month high of $7.95.

PainReform (NASDAQ:PRFX) last issued its quarterly earnings results on Thursday, September 3rd. The company reported ($1.13) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research note on Friday, July 17th. Wall Street Zen upgraded shares of PainReform to a “sell” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of “Sell”.

About PainReform

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s goal is to provide longer-lasting pain relief at the surgical site while potentially reducing reliance on opioid medications after surgery.

PainReform’s lead product candidate, PRF-110, is an investigational extended-release formulation of the local anesthetic ropivacaine. The product is designed to be administered directly into a surgical site and provide pain relief for up to approximately 72 hours following a procedure.